AstraZeneca announces its $15.6B acquisition of MedImmune. Investors send the company's stock down because the high price tag is seen as excessive.
AstraZeneca suffers another steep setback when a European court removes patent protection from AstraZeneca's top seller in Europe. Investors punish the company's stock.